QL1706 + paclitaxel + bevacizumab

QL1706 + paclitaxel + bevacizumab is an investigational combination therapy comprising QL1706, paclitaxel, and bevacizumab. **QL1706** is a novel bifunctional antibody developed by Qilu Pharmaceutical, designed as a dual immune checkpoint inhibitor that targets both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), combining anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies from a single cell line. **Paclitaxel** is a chemotherapy agent that stabilizes microtubules and inhibits cell division, while **bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis. This combination is being studied as a first-line therapy in several cancer indications including advanced non-small cell lung cancer (NSCLC) and recurrent or metastatic cervical cancer. Early clinical data suggest the combination is tolerable and shows promising antitumor activity, including in populations with EGFR-mutant NSCLC who have progressed on prior tyrosine kinase inhibitor therapy[1][5].